Parker Waichman LLP

Medtronic Infuse Sales Decline as Controversy Grows

In recent months, the controversy surrounding Medtronic Inc.’s Infuse bone growth product has gained momentum. Not only has the device maker been accused of downplaying the serious side effects associated with Infuse, but most recently, a prominent researcher warned that Infuse may be associated with a higher risk of developing cancer. Not surprisingly, Medtronic’s spine […]

In recent months, the controversy surrounding Medtronic Inc.’s Infuse bone growth product has gained momentum. Not only has the device maker been accused of downplaying the serious side effects associated with Infuse, but most recently, a prominent researcher warned that Infuse may be associated with a higher risk of developing cancer. Not surprisingly, Medtronic’s spine business is suffering, and it appears Infuse is to blame. According to Medtronic press release, its core spinal revenue declined by 3 percent in the second quarter compared to last year. At the same time, the biologics portion of Medtronic’s spine business declined by 4 percent, thanks to a drop in Infuse sales.

Medtronic’s Infuse bone graft system consists of the LT-Cage Device – a small, hollow metal cylinder – which is filled with genetically engineered material, known as rhBMP-2 (recombinant human Bone Morphogenetic Protein-2), which stimulates bone growth. In 2002, the U.S. Food and Drug Administration (FDA) approved the Infuse system for use in one type of spine surgery – anterior approach lumbar fusion. While Infuse was later approved for use in two types of dental surgeries, it was never approved for any other spine surgery.

Since its approval, Infuse has been at the center of several controversies. Most recently, questions have been raised about Medtronic-sponsored research that may have downplayed serious side effects. And earlier this month, new research linked Infuse to an increased risk of cancer. Both of those issues were raised by Dr. Eugene Carragee, a Stanford University orthopedic surgeon and editor of The Spine Journal.

Over the summer, Carragee authored an article for The Spine Journal in which he disclosed that Medtronic-paid surgeons had failed to report serious complications from Infuse, including cancer, sterility in men, infections, bone dissolution and worsened back and leg pain. The article said complications occurred in 10 to 50 percent of patients who got the product in 13 Medtronic-funded clinical trials between 2000 and 2010. Dr. Carragee’s article appeared in the June issue of The Spine Journal, which was devoted, in its entirety, to a review of rhBMP. Carragee’s review examined payment data from Medtronic to doctors who co-authored the Infuse studies, and found that, the median amount to the company paid to doctors was at least $12 million to $16 million per study (though it should be noted that none of the royalty payments related to Infuse.)

Earlier this month, Carragee again made news when he presented a study at the North American Spine Society that raised serious questions about a possible association between Infuse and an increased risk of cancer. Carragee’s analysis of a Medtronic study for its Amplify product, a higher-dose version of rhBMP-2, found that the study failed to identify a significant cancer risk though both the research team and Medtronic were aware of data linking the product to cancer. Again, the researchers had received millions in royalties from Medtronic (though again, the payments were not related to rhBMP-2 products). The study was submitted to the FDA in order to obtain approval for Amplify; however the FDA declined to approve Amplify, citing the product’s association with a higher incidence of cancer.

The study analyzed by Carragee involved 239 patients who got the Amplify product and 224 who got a conventional graft of their own hip bone. After three years, 5% of those who got Amplify, or 12 patients, were diagnosed with a new cancer, compared with 1.3%, or three patients, who got a graft of their own hip bone. The difference was statistically significant. In an interview with The New York Times, Carragee said the cancer findings could have serious implications for people receiving Infuse. Doctors often administer Infuse off-label at levels significantly above the recommended dosages, ones that approach or exceed the amount of rhBMP-2 found in a dose of Amplify, he said.

Unfortunately, it does appear that Infuse is frequently used off-label. In 2008, the FDA warned that Infuse Bone Graft and similar products had caused serious problems when they were used off-label in cervical spine (neck) surgeries. Injuries associated with off-label use of Infuse can include ectopic or uncontrolled bone growth at or near the site of the surgery; ongoing or chronic radiating pain in the legs or arms (i.e., neuritis, radiculopathy, or radiculitis); sterility, retrograde ejaculation, or other uro-genital injuries in male patients; nerve injuries causing severe and chronic pain. In cervical spine surgeries some patients experience acute severe neck swelling several days after surgery resulting in death or permanent injury.

The U.S. Senate Finance Committee has been investigating Infuse for several years, and recently – thanks to Carragee’s Spine Journal article – demanded Medtronic turn over records detailing payments made to infuse researchers. Meanwhile, the U.S. Justice Department is investigating off-label use of Infuse.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness , Value I have a claim with the 9/11 Victim Compensation Fund which Parker Waichman has guided me through. They have made the process easy and understandable. I would like to thank all the lawyers and paralegals for the kindness they have shown especially Christina Morace.
Dale Bosco
3 years ago
5 Star Reviews 150
Excellent service, I am very grateful for what they did for my accident case and I thank Ana Palacios for her attention and kindness and I recommend all the staff for your case.
Erasmo Garcia
8 months ago
5 Star Reviews 150
It was a pleasure to work with Julie Trinidad as my case manager at Parker Waichman, she did a great job on my case!!!.
Ignacio Tamarez
6 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038